Demand for Taenia solium cysticercosis vaccine: lessons and insights from the Ugandan pig value chain
Taenia solium cysticercosis disease remains a key challenge to the pig sector in low- and middle-income countries in sub-Saharan Africa, Latin America and Southeast Asia, resulting in economic losses and public health impacts.
The World Health Organization has ranked it first on the global scale of foodborne parasites. A One Health approach has been recommended for reduction of infection pressure and eradication in the longer term.
A new vaccine TSOL18 (Cysvax™), applied in combination with oxfendazole (Paranthic 10%™), a dewormer drug has been developed and field tested for the control of T. solium cysticercosis, with high potential to break the disease cycle.
It is, however, unclear whether the products can be marketed through a market driven approach, and if smallholder pig farmers would be willing to take up and pay for the vaccine–oxfendazole combination.
Therefore, this study assessed the potential demand and willingness to pay for the vaccine—oxfendazole combination by Ugandan smallholder pig farmers, and demand for vaccinated pigs by pig traders.